Giredestrant and Everolimus: The Dual Approach Transforming ER-Positive Breast Cancer Treatment
Advancements in cancer treatment have highlighted the role of oral drug combinations for patients with advanced ER-positive breast cancer. ER-positive subtype comprises about 70% of all breast cancer cases. Innovative therapeutic strategies are being sought to improve patient outcomes, as current treatments often fall short. The phase 3 evERA Breast Cancer study revealed giredestrant’s impact: […]



